Amisulpride in the Prevention of Nausea and Vomiting Induced by Cisplatin-based Chemotherapy: a Dose-escalation Study

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2017 Aug 13

PMID 28801850

Citations 2

Authors

Jorn Herrstedt

Yvonne Summers

Gedske Daugaard

Thomas B Christensen

Karin Holmskov

Paul D Taylor

Gabriel M Fox

Alexander Molassiotis

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study was to investigate the antiemetic effect of the dopamine D- and dopamine D-receptor antagonist, amisulpride, in patients receiving cisplatin-based chemotherapy.

Methods: This dose-finding, non-comparative study investigated the antiemetic effect and safety of increasing doses (2.5, 7.5 and 20 mg) of amisulpride against acute nausea and vomiting in the period 0-24 h after initiation of cisplatin-based chemotherapy. The 20 mg dose was also investigated in combination with the 5-HT-receptor antagonist, ondansetron. The primary parameter was complete response (0-24 h), defined as no emesis and no need for rescue antiemetics. Secondary parameters were number of emetic episodes, severity of nausea and time to first emetic episode and start of nausea.

Results: A total of 51 patients were enrolled and evaluable. None of the 10 patients in the 2.5 and 7.5 mg groups obtained a CR. In the 20 mg monotherapy cohort, two of the 18 subjects (11%) had a CR, 3/18 (17%) had no emesis and 12/18 (67%) had no significant nausea. Seven subjects (39%) had no nausea at all (a VAS score < 5 mm). In the combination (ondansetron plus amisulpride) cohort, 19/23 (83%; 90% confidence interval: 65-94%) had a CR and 14/23 (61%) had no nausea at all.

Conclusions: Amisulpride has antiemetic effect against cisplatin-induced acute nausea and vomiting. The effect against nausea is of particular interest. Randomised studies are warranted to further explore the effect and safety of amisulpride.

Citing Articles

Metabolism and Excretion of Intravenous, Radio-Labeled Amisulpride in Healthy, Adult Volunteers.

Fox G, Roffel A, Hartstra J, Bussian L, van Marle S Clin Pharmacol. 2019; 11:161-169.

PMID: 31819674 PMC: 6896931. DOI: 10.2147/CPAA.S234256.

Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial.

Herrstedt J, Summers Y, Jordan K, von Pawel J, Jakobsen A, Ewertz M Support Care Cancer. 2018; 27(7):2699-2705.

PMID: 30488222 DOI: 10.1007/s00520-018-4564-8.

References

Herrstedt J . Chemotherapy-induced nausea and vomiting with special emphasis on metopimazine. Dan Med Bull. 1998; 45(4):412-22. View

Taubel J, Ferber G, Fox G, Fernandes S, Lorch U, Camm A . Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects. Br J Clin Pharmacol. 2016; 83(2):339-348. PMC: 5237697. DOI: 10.1111/bcp.13128. View

Hesketh P, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I . Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014; 25(7):1340-1346. PMC: 4071755. DOI: 10.1093/annonc/mdu110. View

Kranke P, Eberhart L, Motsch J, Chassard D, Wallenborn J, Diemunsch P . I.V. APD421 (amisulpride) prevents postoperative nausea and vomiting: a randomized, double-blind, placebo-controlled, multicentre trial. Br J Anaesth. 2013; 111(6):938-45. DOI: 10.1093/bja/aet251. View

Roila F, Tonato M, Cognetti F, Cortesi E, Favalli G, Marangolo M . Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol. 1991; 9(4):675-8. DOI: 10.1200/JCO.1991.9.4.675. View

Navari R, Qin R, Ruddy K, Liu H, Powell S, Bajaj M . Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016; 375(2):134-42. PMC: 5344450. DOI: 10.1056/NEJMoa1515725. View

Hesketh P, Grunberg S, Gralla R, Warr D, Roila F, de Wit R . The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052.... J Clin Oncol. 2003; 21(22):4112-9. DOI: 10.1200/JCO.2003.01.095. View

Darmani N, Zhao W, Ahmad B . The role of D2 and D3 dopamine receptors in the mediation of emesis in Cryptotis parva (the least shrew). J Neural Transm (Vienna). 2000; 106(11-12):1045-61. DOI: 10.1007/s007020050222. View

Simon R . Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10(1):1-10. DOI: 10.1016/0197-2456(89)90015-9. View

10.

Bloechl-Daum B, Deuson R, Mavros P, Hansen M, Herrstedt J . Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006; 24(27):4472-8. DOI: 10.1200/JCO.2006.05.6382. View

11.

Spina E, De Leon J . Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007; 100(1):4-22. DOI: 10.1111/j.1742-7843.2007.00017.x. View

12.

MOERTEL C, Reitemeier R . Controlled clinical studies of orally administered antiemetic drugs. Gastroenterology. 1969; 57(3):262-8. View

13.

Coulouvrat C . Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol. 1999; 14(4):209-18. DOI: 10.1097/00004850-199907000-00002. View

14.

Abbas A, Hedlund P, Huang X, Tran T, Meltzer H, Roth B . Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl). 2009; 205(1):119-28. PMC: 2821721. DOI: 10.1007/s00213-009-1521-8. View

15.

Smyth J, Coleman R, Nicolson M, Gallmeier W, Leonard R, Cornbleet M . Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?. BMJ. 1991; 303(6815):1423-6. PMC: 1671686. DOI: 10.1136/bmj.303.6815.1423. View

16.

Herrstedt J, Sigsgaard T, Handberg J, Schousboe B, Hansen M, Dombernowsky P . Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer. J Clin Oncol. 1997; 15(4):1690-6. DOI: 10.1200/JCO.1997.15.4.1690. View

17.

Hesketh P . Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008; 358(23):2482-94. DOI: 10.1056/NEJMra0706547. View

18.

Kris M, Gralla R, Clark R, Tyson L, OConnell J, Wertheim M . Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol. 1985; 3(10):1379-84. DOI: 10.1200/JCO.1985.3.10.1379. View

19.

Pierce P, Xie G, Levine J, Peroutka S . 5-Hydroxytryptamine receptor subtype messenger RNAs in rat peripheral sensory and sympathetic ganglia: a polymerase chain reaction study. Neuroscience. 1996; 70(2):553-9. DOI: 10.1016/0306-4522(95)00329-0. View

20.

Grunberg S, Gala K, Lampenfeld M, Jamin D, Johnson K, Cariffe P . Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study. J Clin Oncol. 1984; 2(7):782-7. DOI: 10.1200/JCO.1984.2.7.782. View